Cas:950184-00-6 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside manufacturer & supplier

Chemical Name:4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside

CAS.NO:950184-00-6

Synonyms:4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside

Molecular Formula:C₂₅H₂₈O₉

Molecular Weight:472.48400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:719.8±60.0 °C (760 mmHg)

Density:1.366±0.06 g/cm3 (20 °C, 760 mmHg)

Index of Refraction:

PSA:142.75000

Exact Mass:472.17300

LogP:1.35680

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside Use and application,4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside technical grade,usp/ep/jp grade.

Related News: The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside manufacturer Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside vendor In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth. 4-(3-oxobutyl)phenyl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-b-D-glucopyranoside factory In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.